NASDAQ$AXGN
Axogen Inc. · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Axogen's financial performance reflected revenue growth and efforts to manage net losses.
Axogen reported an 11% increase in revenue to $38.2 million for the second quarter of 2023 compared to the same period in 2022. The company experienced a net loss of $6.7 million, an improvement from the $7.7 million net loss in the second quarter of 2022. The company maintains full-year 2023 revenue guidance in the range of $154 million to $159 million.
- Revenue increased by approximately 11% to $38.2 million compared to the second quarter of 2022.
- Revenues from scheduled non-trauma procedures grew over 20% year-over-year and represented approximately half of total revenues.
- Gross margin was 81.1%, slightly lower than 81.8% in the second quarter of 2022.
- Net loss improved to $6.7 million, or $0.16 per share, from a net loss of $7.7 million, or $0.18 per share, in the second quarter of 2022.
Headline financials
Revenue & EPS history
Axogen · Revenue · Quarterly
$38.2M
Forward guidance
Management is maintaining full-year 2023 revenue guidance in the range of $154 million to $159 million, which represents annual growth of 11% - 15%. The Company anticipates that gross margin will be reduced with the transition to the new processing facility in the third and fourth quarters and that gross margins for the full year 2023 will be approximately 80%.
Tailwinds
- Full-year 2023 revenue guidance is maintained in the range of $154 million to $159 million.
- Revenue guidance represents annual growth of 11% - 15%.
- The company expects to begin the BLA submission in the first quarter of 2024 and complete the submission in the second quarter of 2024.
- The company believes this process will support BLA approval in the first half 2025.
- The Company successfully initiated the pilot launch of the Axoguard HA+ Nerve Protector™ in the second quarter and will fully launch this extension of its nerve protection platform later this month.
Headwinds
- Gross margin is anticipated to be reduced with the transition to the new processing facility in the third and fourth quarters.
- Gross margins for the full year 2023 will be approximately 80%.
- Emergent trauma procedures continue to experience headwinds as hospitals prioritize resources and address operating challenges particularly with routine trauma procedures.
- The company experienced a net loss of $6.7 million.
- Construction of the APC and in the second quarter placed into service the warehouse and office spaces, and now expects to begin processing tissue in the new facility later this month.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2023
+1.4%
Avg return
Earnings day
+2.4%
Avg return
5 days after
+6.1%
Avg return
30 days after
52%
33 / 64 earnings
Positive
+39.1%
Q2 2024
Best reaction
-27.3%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.6% | +9.9% | +2.6% | |
| Q4 2025 | -6.6% | -10.3% | -8.8% | |
| Q3 2025 | +22.8% | +28.6% | +58.5% | |
| Q1 2025 | -23.2% | -33.6% | -33.4% | |
| Q4 2024 | +11.7% | +11.1% | +5.4% | |
| Q3 2024 | -17.4% | -13.4% | -2.7% | |
| Q2 2024 | +39.1% | +42.2% | +64.4% | |
| Q1 2024 | -11.7% | -11.1% | +4.1% | |
| Q4 2023 | -14.4% | -17.4% | -26.7% | |
| Q3 2023 | +37.4% | +27.7% | +88.8% | |
| Q2 2023 | -20.8% | -27.9% | -27.0% | |
| Q1 2023 | -1.8% | -4.6% | -0.8% | |
| Q4 2022 | +11.6% | +9.2% | +37.8% | |
| Q3 2022 | +19.0% | +21.4% | +0.6% | |
| Q2 2022 | +2.1% | +1.2% | -10.7% | |
| Q1 2022 | +23.4% | +17.7% | +16.8% | |
| Q4 2021 | +8.0% | +27.1% | +6.2% | |
| Q3 2021 | -13.3% | -6.0% | -37.3% | |
| Q2 2021 | -2.5% | -9.5% | -12.5% | |
| Q1 2021 | +14.9% | +13.3% | -1.2% | |
| Q4 2020 | +3.6% | +7.0% | -7.7% | |
| Q3 2020 | +3.4% | +10.4% | +18.0% | |
| Q2 2020 | +0.3% | -2.3% | -1.7% | |
| Q1 2020 | -14.7% | -9.6% | +10.9% | |
| Q4 2019 | -17.6% | -15.8% | -36.3% | |
| Q3 2019 | +12.4% | +13.3% | +23.8% | |
| Q2 2019 | -27.3% | -21.8% | -5.5% | |
| Q1 2019 | -2.1% | -5.4% | -15.7% | |
| Q4 2018 | +1.6% | +6.7% | +13.4% | |
| Q3 2018 | +9.3% | +12.8% | -1.3% | |
| Q2 2018 | -12.6% | -13.1% | -2.4% | |
| Q1 2018 | -5.1% | +5.2% | +14.2% | |
| Q4 2017 | +8.8% | +4.5% | +17.0% | |
| Q3 2017 | +10.7% | +15.3% | +28.5% | |
| Q2 2017 | -4.8% | -6.4% | +14.7% | |
| Q1 2017 | +3.3% | +3.7% | +25.6% | |
| Q4 2016 | -0.5% | -0.5% | -5.2% | |
| Q3 2016 | -1.7% | -10.9% | -7.4% | |
| Q2 2016 | +25.1% | +26.2% | +32.9% | |
| Q1 2016 | -0.4% | — | — | |
| Q4 2015 | -4.7% | — | — | |
| Q3 2015 | +17.3% | — | — | |
| Q2 2015 | +5.4% | — | — | |
| Q1 2015 | +3.1% | — | — | |
| Q4 2014 | +3.8% | — | — | |
| Q3 2014 | +5.5% | — | — | |
| Q2 2014 | +1.3% | — | — | |
| Q1 2014 | +1.6% | — | — | |
| Q4 2013 | -8.5% | — | — | |
| Q3 2013 | +1.8% | — | — | |
| Q2 2013 | -0.3% | — | — | |
| Q1 2013 | -14.7% | — | — | |
| Q4 2012 | +4.5% | — | — | |
| Q3 2012 | -1.8% | — | — | |
| Q2 2012 | +18.2% | — | — | |
| Q1 2012 | +0.3% | — | — | |
| Q4 2011 | -4.5% | — | — | |
| Q3 2011 | -14.8% | — | — | |
| Q2 2010 | +0.0% | — | — | |
| Q2 2011 | +0.0% | — | — | |
| Q1 2011 | +0.0% | — | — | |
| Q4 2010 | -6.8% | — | — | |
| Q3 2010 | +9.7% | — | — | |
| Q1 2010 | -0.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro